Prurigo Nodularis: A historic perspective
- PMID: 40154812
- DOI: 10.1016/j.clindermatol.2025.03.006
Prurigo Nodularis: A historic perspective
Abstract
Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by firm, itchy nodules and relentless itch. PN was first described in the 19th century. After observations of various dermatologists, the clinical presentation was officially given a name in 1909 by James Nevins Hyde. Throughout the 1900s, PN gained pockets of attention concerning its histopathologic features, epidemiology, and pathophysiology, although it existed as a largely ambiguous disease for many years. Only at the turn of the 21st century was the recognition of PN reignited, prompting extensive research and leading to striking advancements in our understanding of the mechanisms that had contributed to PN during the last decade. Despite a long and inconsistent course, there are now definitive immune and neural pathways that can be selectively targeted with novel therapies, suggesting a promising future for managing this debilitating condition.
Copyright © 2025. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest Dr Yosipovitch receives grants from Sanofi; Regeneron Pharmaceuticals, Inc; Pfizer; Escient; Novartis; Eli Lilly; Celldex; and Kiniksa Pharmaceuticals. Dr Yosipovitch participates on an advisory board for Abbvie; Escient Health; Eli Lilly; Galderna; LEO Pharma; Novartis; Pfizer; Pierre Fabre; Regeneron Pharmaceuticals, Inc; Sanofi; Trevitherapeutics; Vifor; Kamari; and GSK. Dr Yosipovitch receives consulting fees from Abbvie; Arcutis; Escient Health; Eli Lilly; Galderma; LEO Pharma; Novartis; Pfizer; Pierre Fabre; Regeneron Pharmaceuticals, Inc; Sanofi; Trevitherapeutics; Vifor; Kamari; and Kiniksa. He holds a patent for topical acetaminophen. The remainder of the authors have no conflicts of interest to report.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
